HEALTH CATALYST INC (HCAT)
US42225T1079 - Common Stock
We assign a fundamental rating of 3 out of 10 to HCAT. HCAT was compared to 40 industry peers in the Health Care Technology industry. HCAT has a bad profitability rating. Also its financial health evaluation is rather negative. HCAT is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
HCAT had positive earnings in the past year.
HCAT had a negative operating cash flow in the past year.
In the past 5 years HCAT always reported negative net income.
HCAT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
HCAT has a Return On Assets of -16.83%. This is in the better half of the industry: HCAT outperforms 61.54% of its industry peers.
HCAT has a Return On Equity (-32.20%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.83% | ||
| ROE | -32.2% | ||
| ROIC | N/A |
ROA(3y)-17.84%
ROA(5y)-30.62%
ROE(3y)-31.29%
ROE(5y)-51.12%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 45.56%, HCAT is not doing good in the industry: 64.10% of the companies in the same industry are doing better.
HCAT's Gross Margin has been stable in the last couple of years.
HCAT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 45.56% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.79%
GM growth 5Y-0.54%
2. Health
2.1 Basic Checks
HCAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HCAT has more shares outstanding
The number of shares outstanding for HCAT has been increased compared to 5 years ago.
HCAT has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -1.03, we must say that HCAT is in the distress zone and has some risk of bankruptcy.
HCAT's Altman-Z score of -1.03 is on the low side compared to the rest of the industry. HCAT is outperformed by 61.54% of its industry peers.
HCAT has a Debt/Equity ratio of 0.62. This is a neutral value indicating HCAT is somewhat dependend on debt financing.
The Debt to Equity ratio of HCAT (0.62) is worse than 64.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.62 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.03 |
ROIC/WACCN/A
WACC9.1%
2.3 Liquidity
HCAT has a Current Ratio of 4.42. This indicates that HCAT is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 4.42, HCAT belongs to the best of the industry, outperforming 82.05% of the companies in the same industry.
A Quick Ratio of 4.42 indicates that HCAT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.42, HCAT belongs to the top of the industry, outperforming 82.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.42 | ||
| Quick Ratio | 4.42 |
3. Growth
3.1 Past
HCAT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 155.56%, which is quite impressive.
Looking at the last year, HCAT shows a small growth in Revenue. The Revenue has grown by 7.13% in the last year.
The Revenue has been growing by 21.32% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)155.56%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q140%
Revenue 1Y (TTM)7.13%
Revenue growth 3Y16.16%
Revenue growth 5Y21.32%
Revenue growth Q2Q8.57%
3.2 Future
HCAT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 76.65% yearly.
Based on estimates for the next years, HCAT will show a quite strong growth in Revenue. The Revenue will grow by 10.63% on average per year.
EPS Next Y117.74%
EPS Next 2Y85.08%
EPS Next 3Y76.65%
EPS Next 5YN/A
Revenue Next Year5.24%
Revenue Next 2Y8.28%
Revenue Next 3Y10.63%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
HCAT is valuated quite expensively with a Price/Earnings ratio of 43.60.
HCAT's Price/Earnings ratio is a bit cheaper when compared to the industry. HCAT is cheaper than 79.49% of the companies in the same industry.
HCAT's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.06.
The Price/Forward Earnings ratio is 20.02, which indicates a rather expensive current valuation of HCAT.
HCAT's Price/Forward Earnings ratio is rather cheap when compared to the industry. HCAT is cheaper than 92.31% of the companies in the same industry.
HCAT's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 20.72.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.6 | ||
| Fwd PE | 20.02 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as HCAT's earnings are expected to grow with 76.65% in the coming years.
PEG (NY)0.37
PEG (5Y)N/A
EPS Next 2Y85.08%
EPS Next 3Y76.65%
5. Dividend
5.1 Amount
No dividends for HCAT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HEALTH CATALYST INC
NASDAQ:HCAT (5/2/2024, 7:00:01 PM)
After market: 6.54 0 (0%)6.54
+0.23 (+3.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap382.98M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.6 | ||
| Fwd PE | 20.02 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.37
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.83% | ||
| ROE | -32.2% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 45.56% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.42
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.62 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.42 | ||
| Quick Ratio | 4.42 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)155.56%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y117.74%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)7.13%
Revenue growth 3Y16.16%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y